Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in Italy

Talamonti, Mark S.; Galluzzo, Marco; Chiricozzi, Andrea; Quaglino, Pietro; Fabbrocini, Gabriella; Gisondi, Paolo; Marzano, Angelo Valerio; Potenza, Concetta; Conti, Andrea; Parodi, Angelica; Fortina, Anna Belloni; Bardazzi, Federico; Argenziano, Giuseppe; Rongioletti, Franco; Stingeni, Luca; Micali, Giuseppe; Loconsole, Francesco; Venturini, Marina; Bongiorno, Maria Rita; Feliciani, Claudio; Rubegni, Pietro; Amerio, Paolo; Fargnoli, Maria Concetta; Pigatto, Paolo D.; Savoia, Paola; Nisticò, Steven Paul; Giustini, Sandra; Carugno, Andrea; Cannavò, Serafinella Patrizia; Rech, Giulia; Prignano, Francesca; Offidani, Annamaria; Lombardo, M.; Zalaudek, Iris; Bianchi, Luca; Peris, Ketty; Balestri, Riccardo; Bernardini, Nicoletta; Botti, Elisabetta; Burlando, Martina; Caldarola, Giacomo; Cattaneo, Angelo; Dapavo, Paolo; Dastoli, Stefano; Simone, Clara De; Nuzzo, Sergio Di; Diotallevi, Federico; Fierro, Margarita; Fidanza, Rosaria; Foti, Caterina; Gambini, D; Gambardella, Alessio; Girolomoni, Giampiero; Guarneri, Claudio; Gualdi, Giulio; Hansel, C.; Megna, Matteo; Mugheddu, Cristina; Musumeci, Maria Letizia; Patrizi, Annalisa; Pellacani, Giovanni; Piaserico, Stefano; Richetta, Antonio Giovanni; Rosi, Elia; Rossi, Maria Teresa; Sacchelli, Lidia; Tiberio, Rossana; Tilotta, Giovanna; Trovato, Emanuele; Vezzoni, Roberta; Zangrilli, Arianna

doi:10.1111/jdv.16841

Cited by 32 publications

(34 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Curiously, these two patients were fairly young, both 33 years, hence with a lower death risk for COVID‐19. Comparing our results with those of other recently published studies, our rate of discontinued therapies is much lower 5,6 . Undoubtedly, in the total result, the smallest sample certainly had an influence.…”

Section: Patients Who Stopped Treatment Patients Who Extended the Dossupporting

confidence: 77%

See 1 more Smart Citation

Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Patients Who Stopped Treatment Patients Who Extended the Dossupporting

confidence: 77%

“…Comparing our results with those of other recently published studies, our rate of discontinued therapies is much lower. 5,6 Undoubtedly, in the total result, the smallest sample certainly had an influence.…”

mentioning

confidence: 95%

Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In fact, our study was conducted during the first 4 months of pandemic in Central Italy, where SARS-CoV-2 infection incidence was considerably lower than in Northern Italy, 6 and to date studies regarding the management of biologic therapies during COVID-19 emergency are rare. 7…”

mentioning

confidence: 99%

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic

Hansel

Zangrilli

Bianchi

et al. 2020

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

“…PSO-BIO-COVID is an observational, multicentric study, supported by the Italian Society of Dermatology (SIDeMaST), which aimed at evaluating the impact of SARS-CoV-2 infection on the management of patients with psoriasis in Italy during the first year of the pandemic [ 75 ]. Patients with moderate-to-severe chronic plaque psoriasis, aged > 18 years, and receiving any biological agent as of 22 February 2020, were enrolled.…”

Section: Biologics For Psoriasismentioning

confidence: 99%

Biologics for Psoriasis during the COVID-19 Pandemic

Komine

Ohtsuki

2021

JCM

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19.

show abstract

Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in Italy

Abstract: Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock: a case report.

Cited by 32 publications

References 8 publications

Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic

Biologics for Psoriasis during the COVID-19 Pandemic

Contact Info

Product

Resources

About